Serina Therapeutics, Inc. (SER)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 1.5M 3M 4.5M Q1 '21: 56K Q2 '21: 37K Q3 '21: 24K Q4 '21: 27K Q1 '22: 5K Q2 '22: 12K Q3 '22: 9K Q4 '22: 8K Q1 '23: 30K Q2 '23: 7K Q3 '23: 29K Q4 '23: 3.1M Q1 '24: 5K Q2 '24: 51K Q3 '24: 14K Q1 '25: 0 Q2 '25: 130K Q3 '25: 0 Q4 '25: 0 Q2 '26: 0 Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q2 '25 Q2 '26

Gross Profit Quarterly

0 200K 400K 600K Q1 '19: 325K Q2 '19: 327K Q3 '19: 362K Q4 '19: 470K Q1 '20: 88K Q2 '20: 42K Q3 '20: 52K Q4 '20: 153K Q1 '21: 53K Q2 '21: 24K Q3 '21: 22K Q4 '21: 26K Q1 '22: 4K Q2 '22: 6K Q3 '22: 4K Q4 '22: 7K Q1 '23: 9K Q2 '23: 4K Q3 '23: 34K Q4 '23: 55K Q2 '19 Q1 '20 Q4 '20 Q3 '21 Q2 '22 Q1 '23 Q4 '23

Operating Income Quarterly

-7.5M -5M -2.5M 0 2.5M 5M 7.5M Q2 '21: -2.2M Q3 '21: -1.7M Q4 '21: -1.9M Q1 '22: -2.1M Q2 '22: -1.6M Q3 '22: -1.6M Q4 '22: -1.8M Q1 '23: -962K Q2 '23: -945K Q3 '23: -1.5M Q4 '23: 241K Q1 '24: -2.3M Q2 '24: -3.9M Q3 '24: -5.3M Q4 '24: -5.5M Q1 '25: -5.9M Q2 '25: -5.6M Q3 '25: -6.4M Q4 '25: -6.2M Q2 '26: -6.8M Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q2 '26

Net Income Quarterly

-18M -12M -6M 0 6M 12M 18M Q3 '21: -2M Q4 '21: -2.2M Q1 '22: -2.7M Q2 '22: -2.6M Q3 '22: -2.4M Q4 '22: -2.7M Q1 '23: 1.7M Q2 '23: 808K Q3 '23: 1.8M Q4 '23: 1.1M Q1 '24: -15M Q2 '24: 5.2M Q3 '24: 1.4M Q4 '24: -2.7M Q1 '25: -4.8M Q2 '25: -6.4M Q3 '25: -4.6M Q4 '25: -3.3M Q1 '26: -6.9M Q2 '26: -6.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 30K 60K 90K Q1 '19: 63K Q2 '19: 53K Q3 '19: 49K Q4 '19: 79K Q1 '20: 1K Q2 '20: 3K Q3 '20: 17K Q4 '20: 5K Q1 '21: 3K Q2 '21: 13K Q3 '21: 2K Q4 '21: 1K Q1 '22: 1K Q2 '22: 6K Q3 '22: 5K Q4 '22: 1K Q1 '23: 1K Q2 '23: 5K Q3 '23: 33K Q4 '23: 1K Q2 '19 Q1 '20 Q4 '20 Q3 '21 Q2 '22 Q1 '23 Q4 '23

Operating Cash Flow Quarterly

-9M -6M -3M 0 3M 6M 9M Q3 '21: -1.9M Q4 '21: -1.6M Q1 '22: -1.6M Q2 '22: -1.7M Q3 '22: -1.2M Q4 '22: -1.3M Q1 '23: -709K Q2 '23: -864K Q3 '23: -1M Q4 '23: 121K Q1 '24: -1.6M Q2 '24: -8M Q3 '24: -3M Q4 '24: -4.6M Q1 '25: -4.3M Q2 '25: -3.8M Q3 '25: -3.9M Q4 '25: -6M Q1 '26: -4.6M Q2 '26: -6.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-9M -6M -3M 0 3M 6M 9M Q4 '18: -2M Q1 '19: -2.6M Q2 '19: -2.9M Q3 '19: -2.6M Q4 '19: -2.7M Q1 '20: -2.1M Q2 '20: -2.2M Q3 '20: -1.9M Q4 '20: -1.6M Q3 '23: -1.1M Q1 '24: -1.6M Q2 '24: -8M Q3 '24: -3M Q4 '24: -4.6M Q1 '25: -4.3M Q2 '25: -3.8M Q3 '25: -3.9M Q4 '25: -6M Q1 '26: -4.6M Q2 '26: -6.7M Q1 '19 Q4 '19 Q3 '20 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 15M 30M 45M Q1 '21: 37.7M Q2 '21: 37.9K Q3 '21: 37.9M Q1 '22: 37.9M Q2 '22: 37.9K Q3 '22: 37.9K Q1 '23: 8.6M Q2 '23: 7.4K Q3 '23: 7.6M Q1 '24: 2.8M Q2 '24: 10.2M Q3 '24: 10.8M Q1 '25: 9.8M Q2 '25: 10M Q3 '25: 10.3M Q1 '26: 12M Q2 '26: 16.4M Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-6.00 -4.00 -2.00 0.00 2.00 4.00 6.00 Q4 '18: -0.22 Q1 '19: -0.30 Q2 '19: -0.32 Q3 '19: -0.35 Q4 '19: -0.34 Q1 '20: -0.33 Q2 '20: -0.32 Q3 '20: -0.30 Q4 '20: -0.29 Q1 '21: -0.27 Q2 '24: -4.48 Q3 '24: -4.58 Q4 '25: -1.91 Q1 '26: -2.00 Q2 '26: -1.89 Q4 '18 Q2 '19 Q4 '19 Q2 '20 Q4 '20 Q2 '24 Q4 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.